Madrigal Pharmaceuticals Inc
(LTS:0JXI)
$
276.4968
6.4868 (2.4%)
Market Cap: 5.94 Bil
Enterprise Value: 5.00 Bil
PE Ratio: 0
PB Ratio: 6.77
GF Score: 41/100 - Q1 2024 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024$219 (-3.39%)Earnings
- Madrigal Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Madrigal Pharmaceuticals Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call TranscriptJun 24, 2023
- Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Madrigal Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptMay 16, 2023
- Madrigal Pharmaceuticals Inc to Announce Topline Data from the Phase 3 MAESTRO-NASH Study of Resmetirom Presentation TranscriptDec 19, 2022
- Madrigal Pharmaceuticals Inc EASL Investor Event Call TranscriptJun 25, 2022
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 24, 2022
- Q1 2022 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2022$95.17Earnings
- Madrigal Pharmaceuticals Inc Call to Discuss MAESTRO-NAFLD-1 Phase 3 Data TranscriptJan 31, 2022
- Madrigal Pharmaceuticals Inc AASLD The Liver Meeting Call TranscriptNov 16, 2021
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 19, 2020
Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 04:20PM GMT
Release Date Price:
$268.09
(+0.85%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Thank you for joing us on the second day of our 44th Annual Goldman Sachs Conference. We're really pleased to have the team from Madrigal with us, Paul Friedman, CEO; Becky Taub, President of R&D and CMO; Remy Sukhija, Chief Commercial Officer and Alex Howarth, CFO. With that, thank you, guys, for joining us this morning.
Questions & Answers
Andrea R. Tan;Rebecca A. Taub
Goldman Sachs Group, Inc., Research Division - Research Analyst;Madrigal Pharmaceuticals, Inc. - Founder, Chief Medical Officer, President of Research & Development and Director
Paul and Becky, maybe I'll start with you. You guys have been in the NASH space for so many years, leaders in this space. Maybe from a high level, what has the last year meant to you to the space, the progress that's been [named] not only by yourselves, but by your competitors? And then maybe describe to us what it means to be here on the cusp of having the first approved therapy in NASH.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)